| Not Yet Recruiting | Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) NCT07407582 | University of Arizona | Phase 1 / Phase 2 |
| Not Yet Recruiting | Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinica NCT07192315 | Assistance Publique Hopitaux De Marseille | N/A |
| Not Yet Recruiting | Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts. NCT07524140 | Eilean Therapeutics | Phase 1 |
| Not Yet Recruiting | Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression NCT07476534 | The First Affiliated Hospital of Xinxiang Medical College | — |
| Not Yet Recruiting | Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. NCT07303387 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Recruiting | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies NCT07486713 | Rigel Pharmaceuticals | Phase 4 |
| Not Yet Recruiting | Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors NCT07282873 | TYK Medicines, Inc | Phase 1 / Phase 2 |
| Not Yet Recruiting | Malic Acid Supplementation Combined With Immunotherapy in Patients With Solid Tumors NCT07325123 | The First Affiliated Hospital of Xinxiang Medical College | EARLY_Phase 1 |
| Recruiting | CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Meta NCT07476781 | Sunnybrook Health Sciences Centre | N/A |
| Recruiting | A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary NCT07231120 | Jiangsu Nutai Biologics Co., Ltd | Phase 1 |
| Recruiting | xDRIVE for Florida-based Cancer Patients NCT07167381 | First Ascent Biomedical Inc. | N/A |
| Not Yet Recruiting | 68Ga-GP-01 Injection in Solid Tumors Participants NCT07045428 | GrandPharma (China) Co., Ltd. | Phase 1 |
| Recruiting | Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies NCT07174453 | University of Kansas Medical Center | Phase 3 |
| Recruiting | A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies NCT07207707 | Kumquat Biosciences Inc. | Phase 1 |
| Not Yet Recruiting | Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors NCT07182435 | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | EARLY_Phase 1 |
| Recruiting | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors NCT07030257 | Tasca Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic So NCT07181473 | Phrontline Biopharma | Phase 1 |
| Recruiting | A Clinical Study of GO306 in Patients With Advanced Solid Tumors NCT07128914 | GeneSail Biotech (Shanghai) Co., Ltd. | Phase 1 |
| Recruiting | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced NCT06960395 | Vir Biotechnology, Inc. | Phase 1 |
| Recruiting | A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors NCT07071090 | Heronova Pharmaceuticals | Phase 1 |
| Recruiting | PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival NCT06896162 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants Wit NCT06994806 | Kumquat Biosciences Inc. | Phase 1 |
| Recruiting | A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Prelimin NCT07363967 | Beijing StoneWise Technology Co., Ltd | Phase 1 |
| Not Yet Recruiting | A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors NCT07014878 | Beijing DCTY Biotech Co.,Ltd. | Phase 1 |
| Recruiting | A Study of SH009 Injection in Patients With Advanced Solid Tumors. NCT07390838 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 |
| Active Not Recruiting | Serum IGF-1 and IGF-1Ec in Malignancy Assessment NCT07151807 | Çanakkale Onsekiz Mart University | — |
| Recruiting | A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants Wit NCT06720987 | Kumquat Biosciences Inc. | Phase 1 |
| Recruiting | A Single-arm Clinical Trial Using Patient-derived Tumor Tissue Fragment Models for Drug Sensitivity Testing to NCT07264803 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or NCT06136884 | A2A Pharmaceuticals Inc. | Phase 1 |
| Active Not Recruiting | ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies NCT05085548 | ProDa BioTech, LLC | Phase 1 |
| Terminated | ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter NCT04668833 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That NCT01924689 | BioMed Valley Discoveries, Inc | Phase 1 |
| Terminated | Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Sta NCT01118819 | BioMed Valley Discoveries, Inc | Phase 1 |
| Completed | A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors NCT01183364 | Synta Pharmaceuticals Corp. | Phase 1 |
| Terminated | A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Phar NCT01290380 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies NCT00310895 | Geron Corporation | Phase 1 |
| Terminated | Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies NCT00195156 | Weill Medical College of Cornell University | Phase 1 |